MBX-8025 obtained another ODD from the FDA for the treatment of patients with Frederickson Type I or V hyperlipoproteinemia. MBX-8025 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist under development by CymaBay Therapeutics, a biopharmaceutical company based in Newark, NJ. It received ODD from the FDA last month for homozygous familial hypercholesterolemia (HoFH). Hyperlipoproteinemia is a group of disorders with abnormally high levels of any or all lipids and/or lipoproteins in the blood. Familial hyperlipoproteinemia is usually hereditary and Frederickson Type I or V hyperlipoproteinemia is relatively rare among hyperlipoproteinemia. Left untreated, this group of patients would develop premature cardiovascular disease that can result in myocardial infarction, ischemic stroke and premature death. Being a potent agonist for PPARδ, a nuclear receptor important for lipid transport, storage and metabolism in liver and muscle, MBX-8025 has shown favorable effects on lipid and metabolic parameters in clinical trials in patients with dyslipidemia.